China's medical products administrator approved Essex Bio-Technology (HKG:1061) subsidiary Guangdong Hanfeng Baisheng Pharmaceutical's sodium hyaluronate eye drops for use in mainland China, according to a Friday filing with the Hong Kong Stock Exchange.
The preservative-free drug is used for eye conditions such as Sjögren's syndrome which causes dry eyes, Stevens-Johnson syndrome which affects mucous membranes, and other injuries caused by surgery, drugs or contact lens use, the filing said.
Shares closed 1% lower during Monday's trading.
Price (HKD): $2.27, Change: $-0.030, Percent Change: -1.30%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments